Vector Labs Ab04856-23.0 Anti-CD96 [BL006-19-14G3-14K1], Rabbit IgG, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: BL006-19-14G3-14K1
Synonyms: Tactile; T cell activation, increased late expression; Cluster of Differentiation 96
Amount: 100 μg
Application Codes Clone: ELISA; FC; FACS; SPR
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG2a
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody is specific for the D2 domain of the shorter form of human CD96 (isoform v2). It was found to also bind the long for of human CD96, albeit with lower affinity, and to cross-react with Rhesus CD96.
Application Notes: The original antibody (Mouse IgG2a) was selected using ELISA and flow cytometry to confirm binding to CD96. FACS testing showed that this antibody exhibits strong binding to the human CD96 short isoform (CD96v2) expressed on CHO cells (EC₅₀ = 3.10 nM) and strong but weaker binding to the human CD96 long isoform (CD96v1). This antibody showed partial inhibition of the CD96/CD155 interaction, though it did not achieve 50% inhibition at the maximum tested concentration (30 μg/mL, 200 nM), with a relative IC₅₀ calculated at 2.67 nM. FC analysis revealed strong binding to T, NK, and NKT cells from human peripheral blood mononuclear cells (PBMCs). SPR measurement revealed a K_D of 0.254 nM towards an in-house produced hCD96-hFc protein. The antibody demonstrated strong co-stimulatory activity by enhancing T cell activation and proliferation in the presence of suboptimal anti-CD3 stimulation, effectively increasing CD25 expression and CFSE dilution in CD4+ and CD8+ T cells, with Fc receptor cross-linking being required for its activity. When tested in tumor-infiltrating lymphocytes (TILs) extracted from surgically removed head and neck cancer tissues of two patients, the antibody helped invigorate TIL proliferation, particularly under low baseline conditions. It showed its greatest effectiveness when introduced concurrently with suboptimal CD3 stimulation (US20230192845A1).

Product Class:	Purified
Clone ID:	BL006-19-14G3-14K1
Synonyms:	Tactile; T cell activation, increased late expression; Cluster of Differentiation 96
Amount:	100 μg
Application Codes Clone:	ELISA; FC; FACS; SPR
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG2a
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This chimeric rabbit antibody was made using the variable domain sequences of the original Mouse IgG2a format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody is specific for the D2 domain of the shorter form of human CD96 (isoform v2). It was found to also bind the long for of human CD96, albeit with lower affinity, and to cross-react with Rhesus CD96.
Application Notes:	The original antibody (Mouse IgG2a) was selected using ELISA and flow cytometry to confirm binding to CD96. FACS testing showed that this antibody exhibits strong binding to the human CD96 short isoform (CD96v2) expressed on CHO cells (EC₅₀ = 3.10 nM) and strong but weaker binding to the human CD96 long isoform (CD96v1). This antibody showed partial inhibition of the CD96/CD155 interaction, though it did not achieve 50% inhibition at the maximum tested concentration (30 μg/mL, 200 nM), with a relative IC₅₀ calculated at 2.67 nM. FC analysis revealed strong binding to T, NK, and NKT cells from human peripheral blood mononuclear cells (PBMCs). SPR measurement revealed a K_D of 0.254 nM towards an in-house produced hCD96-hFc protein. The antibody demonstrated strong co-stimulatory activity by enhancing T cell activation and proliferation in the presence of suboptimal anti-CD3 stimulation, effectively increasing CD25 expression and CFSE dilution in CD4+ and CD8+ T cells, with Fc receptor cross-linking being required for its activity. When tested in tumor-infiltrating lymphocytes (TILs) extracted from surgically removed head and neck cancer tissues of two patients, the antibody helped invigorate TIL proliferation, particularly under low baseline conditions. It showed its greatest effectiveness when introduced concurrently with suboptimal CD3 stimulation (US20230192845A1).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews